A study investigated three biomarkers (IL-18, hs-CRP and VEGF) as predictors of complications in patients with acute myocardial infarction undergoing coronary intervention[1]. The research involved 170 heart attack patients and 100 healthy subjects who were followed for 12 months[1]. All three biomarkers were significantly increased pre-intervention in infarct patients compared to controls and decreased post-intervention[1]. Patients who had complications during follow-up had significantly higher levels of all three biomarkers before the procedure than patients without complications[1]. Logistic regression confirmed that all three biomarkers were independent predictors of adverse outcomes, with IL-18 having the strongest predictive effect[1]. ROC curve analysis demonstrated an excellent ability to discriminate between patients with good and poor outcomes, with values of 0.803 for IL-18, 0.838 for hs-CRP and 0.800 for VEGF[1]. These biomarkers offer better risk stratification compared to traditional clinical parameters[1].